Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6090 + pemetrexed + platinum-based chemotherapy
- Development stage
- Unknown
- Lead developer
- Shanghai Jinmante Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SYS6090 + pemetrexed + platinum-based chemotherapy is a combination therapeutic regimen being developed by Shanghai JMT-Bio Inc. (a subsidiary of CSPC Pharmaceutical Group) for the treatment of advanced lung cancers. The combination consists of **SYS6090**, a recombinant humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, **pemetrexed**, a folate antimetabolite that inhibits multiple enzymes in the pyrimidine and purine biosynthetic pathways, and a **platinum-based chemotherapeutic agent** (such as cisplatin or carboplatin) which acts as a DNA cross-linking agent. This regimen is currently being evaluated in a Phase Ib/II clinical trial (NCT07472647) specifically targeting patients with driver gene-negative non-squamous non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (SCLC). The combination therapy is designed to enhance anti-tumor activity by combining immune checkpoint inhibition with cytotoxic chemotherapy.
- Other names
- SYS6090 plus pemetrexed and platinum-based chemotherapySYS-6090 plus pemetrexed and platinum-based chemotherapySYS 6090 plus pemetrexed and platinum-based chemotherapy
02
Targets
DHFR (Dihydrofolate reductase)DNAIL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SYS6090 + pemetrexed + platinum-based chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6090 + pemetrexed + platinum-based chemotherapy.